Han Myint

1.7k total citations
30 papers, 1.1k citations indexed

About

Han Myint is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Han Myint has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 12 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Han Myint's work include Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and CAR-T cell therapy research (5 papers). Han Myint is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and CAR-T cell therapy research (5 papers). Han Myint collaborates with scholars based in United States, United Kingdom and Spain. Han Myint's co-authors include Hans Klingemann, Jeff Martinson, Michelle L. Swearingen, Elizabeth Rich, Richard Meagher, Sally Arai, William A. Robinson, David Oscier, Mark Lamotte and K Moeremans and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Han Myint

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Han Myint United States	14	456	453	321	305	245	30	1.1k
Judith Landman‐Parker France	17	434 1.0×	291 0.6×	510 1.6×	262 0.9×	155 0.6×	47	1.5k
Jan Maciej Zaucha Poland	20	443 1.0×	448 1.0×	258 0.8×	757 2.5×	374 1.5×	137	1.7k
Cristiana Carniti Italy	21	439 1.0×	314 0.7×	396 1.2×	392 1.3×	169 0.7×	59	1.2k
Maria Stefania De Propris Italy	19	274 0.6×	264 0.6×	311 1.0×	398 1.3×	436 1.8×	54	1.0k
Francine Garnache‐Ottou France	18	490 1.1×	339 0.7×	306 1.0×	253 0.8×	158 0.6×	54	1.2k
Antonella Bardi Italy	21	240 0.5×	309 0.7×	221 0.7×	460 1.5×	624 2.5×	51	1.2k
Blanca Sánchez‐González Spain	20	304 0.7×	144 0.3×	721 2.2×	598 2.0×	196 0.8×	70	1.5k
Lara Mussolin Italy	20	337 0.7×	240 0.5×	409 1.3×	131 0.4×	109 0.4×	73	1.2k
S N Wolff United States	16	863 1.9×	562 1.2×	423 1.3×	1.1k 3.5×	292 1.2×	22	2.1k
Maurizio Miglino Italy	18	319 0.7×	291 0.6×	220 0.7×	737 2.4×	260 1.1×	65	1.1k

Countries citing papers authored by Han Myint

Since Specialization

Citations

This map shows the geographic impact of Han Myint's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Myint with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Myint more than expected).

Fields of papers citing papers by Han Myint

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Han Myint. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Myint. The network helps show where Han Myint may publish in the future.

Co-authorship network of co-authors of Han Myint

This figure shows the co-authorship network connecting the top 25 collaborators of Han Myint. A scholar is included among the top collaborators of Han Myint based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han Myint. Han Myint is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Short, Nicholas J., Tae Kon Kim, Rustin R. Lovewell, et al.. (2022). A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms. Blood. 140(Supplement 1). 9078–9079. 1 indexed citations

Gutierrez, Martin, Filip Jankú, Linjie Tian, et al.. (2021). A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS2659–TPS2659. 2 indexed citations

Wang, Ruipeng, et al.. (2020). AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties. Transfusion Medicine and Hemotherapy. 47(6). 464–471. 7 indexed citations

Gutman, Jonathan A., Kelly Ross, Clayton A. Smith, et al.. (2016). Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplantation. 51(12). 1588–1593. 37 indexed citations

Mawad, Raya, Pamela S. Becker, Paul C. Hendrie, et al.. (2015). Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high‐risk MDS. British Journal of Haematology. 172(2). 238–245. 24 indexed citations

Herbrecht, Raoul, Paul Cernohous, Andreas Engert, et al.. (2013). Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Annals of Oncology. 24(10). 2618–2623. 36 indexed citations

Forero‐Torres, Andres, Nancy L. Bartlett, Anne Beaven, et al.. (2012). Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 54(2). 277–283. 34 indexed citations

Raza, Azra, Naomi Galili, Scott E. Smith, et al.. (2011). A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome. Cancer. 118(8). 2138–2147. 36 indexed citations

Raza, Azra, Naomi Galili, Scott E. Smith, et al.. (2010). Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood. 116(21). 2910–2910. 2 indexed citations

10.

Epstein, Joel B., et al.. (2009). MEDICAL MANAGEMENT AND PHARMACOLOGY UPDATE. 1 indexed citations

11.

Forero‐Torres, Andres, Nancy L. Bartlett, Sunita D. Nasta, et al.. (2009). A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.. Blood. 114(22). 586–586. 5 indexed citations

12.

Arai, Sally, Richard Meagher, Michelle L. Swearingen, et al.. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 10(6). 625–632. 333 indexed citations

13.

Kröger, Nicolaus, Josè Antonio Pérez-Simón, Han Myint, et al.. (2004). Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood and Marrow Transplantation. 10(10). 698–708. 80 indexed citations

14.

Kröger, Nicolaus, Josè Antonio Pérez-Simón, Han Myint, et al.. (2004). Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood and Marrow Transplantation. 10. 74–74. 1 indexed citations

15.

Annemans, Lieven, K Moeremans, Mark Lamotte, et al.. (2003). Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Supportive Care in Cancer. 11(4). 249–257. 46 indexed citations

16.

Moeremans, K, Mark Lamotte, Henk van den Berg, et al.. (2002). Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries. Leukemia & lymphoma. 44(1). 77–83. 105 indexed citations

17.

Myint, Han, David Oscier, Jennifer Orchard, et al.. (1998). Autoimmune Haemolysis in Patients with B-CLL Treated with Chlorodeoxyadenosine (CDA). Leukemia & lymphoma. 29(3-4). 391–398. 23 indexed citations

18.

Orchard, Jenny, Han Myint, & Terry J. Hamblin. (1997). A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation. Leukemia Research. 21(4). 353–354. 10 indexed citations

19.

Myint, Han, J. A. Copplestone, Jennifer Orchard, et al.. (1995). Fludarabine‐related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 91(2). 341–344. 133 indexed citations

20.

Myint, Han, Joseph Chacko, Sarah Mould, F. Ross, & David Oscier. (1995). Karyotypic evolution in a granulocytic sarcoma developing in a myeloproliferative disorder with a novel (3;4) translocation. British Journal of Haematology. 90(2). 462–464. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact